Meta-Analysis of 5-Fluorouracil-Based Chemotherapy Combined With Traditional Chinese Medicines for Colorectal Cancer Treatment

被引:21
作者
Chen, Peng [1 ,2 ]
Ni, Wei [2 ]
Xie, Tian [1 ,2 ]
Sui, Xinbing [2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China
[2] Hangzhou Normal Univ, Hangzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
5-fluorouracil; colorectal cancer; traditional Chinese medicine; meta-analysis; PREVENT;
D O I
10.1177/1534735419828824
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This meta-analysis evaluates the clinical evidence for the addition of traditional Chinese medicines (TCMs) to 5-fluorouracil (5-FU)-based regimens for colorectal cancer (CRC) in terms of tumor response rate (TRR). Five electronic databases were searched for randomized controlled trials of 5-FU-based chemotherapy combined with TCMs compared to the same 5-FU-based regimen. Forty-five randomized controlled trials were involved in this study, and all the data were analyzed by Stata software (version 14.0). Our results suggested that the TRR of the group with TCMs combined with 5-FU-based regimens was higher than that in the group with 5-FU regimens alone (risk ratio [RR] 1.36 [1.25-1.49], I-2 = 0%). Furthermore, both nonoral administration (RR 1.51 [1.29-1.76], I-2 = 0%) and oral administration (RR 1.31 [1.18-1.45], I-2 = 0%) of TCMs showed benefits to the CRC treatment. Further sensitivity analysis of specific plant-based TCMs found that fuling, sheshecao, banzhilian, eshu, baizhu, huangqi, yiyiren, and dangshen had significantly higher contributions to the results of the risk ratio. Therefore, TCMs may have the potential to improve the efficacy of 5-FU-based chemotherapy for CRC.
引用
收藏
页数:13
相关论文
共 59 条
[31]  
[Anonymous], CLIN IMPACT SHUANGXI
[32]  
[Anonymous], CLIN STUDY QILIAN FU
[33]  
[Anonymous], 2007, Liaoning J Tradit Chin Med (Chin)
[34]  
[Anonymous], PRACT J CANC
[35]  
[Anonymous], JIANGSU J TRADIT CHI
[36]  
[Anonymous], J MOD MED HLTH
[37]   First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study [J].
Aranda, E. ;
Garcia-Alfonso, P. ;
Benavides, M. ;
Sanchez Ruiz, A. ;
Guillen-Ponce, C. ;
Safont, M. J. ;
Alcaide, J. ;
Gomez, A. ;
Lopez, R. ;
Manzano, J. L. ;
Mendez Urena, M. ;
Sastre, J. ;
Rivera, F. ;
Gravalos, C. ;
Garcia, T. ;
Martin-Valades, J. I. ;
Falco, E. ;
Navalon, M. ;
Gonzalez Flores, E. ;
Garcia Tapiador, A. Ma ;
Lopez Munoz, A. Ma ;
Barrajon, E. ;
Reboredo, M. ;
Garcia Teijido, P. ;
Viudez, A. ;
Cardenas, N. ;
Diaz-Rubio, E. .
EUROPEAN JOURNAL OF CANCER, 2018, 101 :263-272
[38]   Yiqi Zhuyu Decoction ((sic)) Combined with FOLFOX-4 as First-Line Therapy in Metastatic Colorectal Cancer [J].
Cao Bo ;
Li Shao-tang ;
Li Zhi ;
Deng Wen-ling .
CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2011, 17 (08) :593-599
[39]   Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J].
Cervantes, A. ;
Adam, R. ;
Rosello, S. ;
Arnold, D. ;
Normanno, N. ;
Taieb, J. ;
Seligmann, J. ;
De Baere, T. ;
Osterlund, P. ;
Yoshino, T. ;
Martinelli, E. .
ANNALS OF ONCOLOGY, 2023, 34 (01) :10-32
[40]   A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer [J].
Chen, Emerson Y. ;
Blanke, Charles D. ;
Haller, Daniel G. ;
Benson, Al B. ;
Dragovich, Tomislav ;
Lenz, Heinz-Josef ;
Robles, Carlos ;
Li, Hong ;
Mori, Motomi ;
Mattek, Nora ;
Sanborn, Rachel E. ;
Lopez, Charles D. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (12) :1193-1198